Skip to main content

Advertisement

Table 1 Patient characteristics

From: [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

Parameter Value
Total number of patients 52
Age, years (mean ± SD) 71.5 ± 9
PSA at first PET/CT (ng/ml), median (IQR) 6.6 (1.3–28.3)
PSA at second PET/CT (ng/ml), median (IQR) 1.6 (0.3–12.1)
Gleason score (n)
 6 6 (11.5%)
 7 2 (3.8%)
 7 (3 + 4) 8 (15.4%)
 7 (4 + 3) 6 (11.5%)
 8 9 (17.3%)
 9 12 (23.1%)
 10 2 (3.8%)
 n/a 7 (13.5%)
Disease extent demonstrated on first PET/CT (n)
 Prostatic disease 29 (55.8%)
 Bone metastases 32 (61.5%)
 Lymph nodes 42 (80.8%)
 Liver metastases 2 (3.8%)
 Peritoneal implants 2 (3.8%)
 Lung metastases 1 (1.9%)
Treatment received between the two PET/CT scans (n)
 Hormonal therapy 42 (80.8%)
 Salvage radiotherapy 17 (32.7%)
 Chemotherapy 12 (23.1%)
 Radium-223 2 (3.8%)